Top Markets
#1 Nesa Nesa +723.56%
#2 Merlin's Seal BTC Merlin's Seal BTC +46.10%
#3 EXOD EXOD +22.78%
#4 Pons Pons +16.35%
#5 Prom Prom +12.83%
#6 Venom Venom +11.01%
#7 Cash Cat Cash Cat +10.00%
#8 Fartcoin Fartcoin +9.34%
#9 PondCoin PondCoin +9.04%
#10 MetaDAO MetaDAO +8.43%
Coin of the day
Nesa Nesa
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Connect Biopharma Holdings Limited Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

CNTB
Peringkat dalam Saham #19722
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical... Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Harga Saham
$2.42
Terakhir disinkronkan: 2026-08-25
Kapitalisasi Pasar
$152.37M
Perubahan (1 hari)
5.22%
Perubahan (1 tahun)
39.88%
Negara
US
Perdagangan Connect Biopharma Holdings Limited (CNTB)

Kategori

Healthcare
Pendapatan untuk Connect Biopharma Holdings Limited (CNTB)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Connect Biopharma Holdings Limited, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Connect Biopharma Holdings Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH